Urban Health Today Editors

Urban Health Today

The predominant front-line treatment regimen for multiple myeloma (MM) over the past nine years was a triplet regimen, most commonly containing an immunomodulatory agent (IMiD), proteasome inhibitor, and a steroid, according to the results of a recent <a href="https://onlinelibrary.wiley.com/doi/10.1002/cam4.4137">study</a>.In fact, the proportion of patients who received triplet regimens increased from around one third (36%) of patients in 2011 to more than two-thirds (72%) in 2019.&ldquo;The breadth and timing of treatment patterns for MM have been examined periodically; however, there is a need to understand the most current real-world treatment practices and outcomes in this rapidly evolving environment,&rdquo; study researchers wrote.To do that, the researchers assessed types of therapies, time to next treatment (TTNT), and overall survival in 6,271 adults diagnosed with MM from the Flatiron Health electronic-health record de-identified database.In 2011, front-line regimens were most often doublets (48%) compared with triplets (36%). However, by 2019 the most common regimens were triplets and the use of doublets decreased by 60%.The median TTNT was 46.7 months during the study period. From 2017 to 2019, the median TTNT from front-line to second-line therapy was longer in patients with International Staging System stage I versus stage II/II disease and those who received an IMiD-based doublet or triplet regimen.The median overall survival was 56 months, with the median decreasing with higher ISS stage. Patients who received triplet regimens had the longest median overall survival of 70 months. From 2011 to 2014, there was a 10-month increase in median overall survival.&ldquo;Of note, the results of our study do not fully reflect the introduction of novel therapies approved for front-line MM in the 2018 to 2019 time period, specifically the anti-CD38 monoclonal antibody daratumumab, with the ALCYONE and MAIA trial results first reported in 2018 and 2019, respectively,&rdquo; the researchers noted. &ldquo;The MM treatment landscape has evolved rapidly and continues to do so, offering new options for patients and treating physicians as reflected in the paradigm shift of prescribed treatments observed in this analysis.&rdquo;

Payton White, BS

How Sleep Quality Influences Risk of Alzheimer’s Disease

Alzheimer's & Dementia

Lou Portero

Hidden Dangers: The Blood Sugar Crisis in Modern Breast Cancer Treatment

Diabetes in Women

New ACG Guidelines Address Critical Gastric Cancer Disparities in Non-White Americans

Gastroenterology

Latest News

Triplet Therapy Is the Predominant Front-Line Regimen for Multiple Myeloma in the US

Multiple Myeloma

The predominant front-line treatment regimen for multiple myeloma (MM) over the past nine years was a triplet regimen, ...

Triplet Therapy: Predominant Front-Line Regimen for Multiple Myeloma in US

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe